In this article, we are going to take a look at where Abacus Global Management, Inc. (NASDAQ:ABL) stands against other small cap stocks with huge upside potential. In times when everyone is ...

The Amended ABL Facility remains at $100 million and was, among other things, extended by over three years to April 2030. The Amended ABL Facility will bear interest at a rate equal to the forward ...

ABL Bio has announced a global licensing agreement with GSK, allowing the latter to develop medicines for neurodegenerative conditions. Through this collaboration, GSK will leverage Grabody-B, a ...

ABL Bio's Grabody-B was developed to overcome the limitations of existing drugs that have difficulty crossing the BBB by targeting the Insulin-like Growth Factor 1 Receptor (IGF1R), facilitating ...

ABL Bio Inc. announced April 7 that it sealed a potential £2.075 billion (US$2.65 billion) license deal with GSK plc, granting GSK global rights to use ABL’s blood-brain barrier (BBB) penetrating ...

ABL Bio has developed its Grabody-B platform to target the insulin-like growth factor 1 receptor (IGF1R) in order to help transport drugs for neurodegenerative disease over the notoriously tricky ...

In this article, we are going to take a look at where Abacus Global Management, Inc. (NASDAQ:ABL) stands against other small cap stocks with huge upside potential. In times when everyone is chasing ...

SEONGNAM, South Korea, April 7, 2025 /PRNewswire/ -- ABL Bio Inc. (KOSDAQ: 298380), a clinical-stage biotech company developing bispecific antibody technology for immuno-oncology and ...